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Objectives This study sought to evaluate whether prasugrel may serve as an alternative to clopidogrel in patients with triple
therapy.
Background Approximately 10% of patients who receive dual antiplatelet therapy after percutaneous coronary intervention
have an indication for oral anticoagulation and are thus treated with triple therapy. The standard adenosine
diphosphate receptor blocker in this setting is clopidogrel. Data regarding prasugrel as part of triple therapy are
not available.
Methods We analyzed a consecutive series of 377 patients who underwent drug-eluting stent implantation and had an
indication for oral anticoagulation between February 2009 and December 2011 and were treated with a
6-month regimen of aspirin and oral anticoagulation with either prasugrel or clopidogrel. The primary endpoint
was a composite of Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding at 6 months. The sec-
ondary endpoint was a composite of death, myocardial infarction, ischemic stroke, or definite stent thrombosis.
Results Twenty-one patients (5.6%) received prasugrel instead of clopidogrel. These patients had a higher-risk profile at
baseline, and the majority had high platelet reactivity to clopidogrel. TIMI major and minor bleeding occurred
significantly more often in the prasugrel compared with the clopidogrel group (6 [28.6%) vs. 24 [6.7%]; unad-
justed hazard ratio (HR): 4.6, 95% confidence interval [CI]: 1.9 to 11.4], p  0.001; adjusted HR: 3.2, 95% CI:
1.1 to 9.1], p  0.03). There was no significant difference regarding the combined ischemic secondary endpoint
(2 [9.5%] vs. 25 [7.0%]; unadjusted HR: 1.4, 95% CI: 0.3 to 6.1], p  0.61).
Conclusions These findings suggest that substitution of prasugrel for clopidogrel in patients needing triple therapy increases
the risk of bleeding. However, specific randomized trials are needed to define the role of newer adenosine
diphosphate receptor antagonists in this setting. (J Am Coll Cardiol 2013;61:2060–6) © 2013 by the
American College of Cardiology FoundationApproximately 5% to 10% of patients undergoing coronary
stenting have an additional indication for oral anticoagula-
tion (OAC) (1) and will thus require a so-called triple
therapy consisting of aspirin, OAC, and an adenosine
diphosphate (ADP) receptor antagonist. The most common
combination currently consists of aspirin, clopidogrel, and a
vitamin K antagonist.
Data from retrospective studies revealed that there is a 3-
to 5-fold increase in bleeding rates associated with this triple
therapy compared with various combinations of dual ther-
apy (2–8). When it comes to ischemic outcomes, however,
a meta-analysis of nonrandomized studies suggested that
triple therapy is more efficacious than dual antiplatelet
therapy in the prevention of major adverse cardiovascular
events and that there is a significant reduction in all-cause
mortality (9). Current guidelines therefore advocate triple
therapy in patients on OAC undergoing coronary stent
implantation (10,11).
See page 2067
For years clopidogrel has been the standard antiplatelet
agent after coronary stent implantation because of its good
safety and efficacy profile (12,13). Its downside, however, is
its nonuniform and rather slow transformation to its active
metabolite, leading to a substantial number of patients who
display on-treatment high platelet reactivity (HPR), a con- wdition associated with a significant increase in ischemic
events (14). Newer antiplatelet drugs such as prasugrel
(15,16) have therefore been developed to overcome clopi-
dogrel’s limitations and recent percutaneous coronary inter-
vention (PCI) guidelines suggest that prasugrel might be
considered an alternative agent in patients treated with
clopidogrel with HPR (12). However, data regarding pra-
sugrel as part of triple therapy are not available.
The purpose of our study was therefore to evaluate
whether prasugrel may serve as an alternative to clopidogrel
in patients with an indication for OAC and drug-eluting
stent (DES) implantation.
Methods
Study population. This is an analysis of prospectively
collected data on patients who presented at Deutsches
Herzzentrum and 1. Medizinische Klinik, Klinikum rechts
der Isar, both in Munich, Germany, between February
2009, when prasugrel was approved in Europe, and Decem-
ber 2011. All patients who underwent DES placement and
were discharged with a 6-month regimen of aspirin, OAC
with phenprocoumon, and an ADP antagonist were in-
cluded. In stable patients on OAC who underwent PCI, the
procedure was postponed until international normalized
ratio (INR) values were 2. In general, bridging therapyas not performed unless patients had a high thromboem-
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valve or a recent thromboembolic
event.
Antiplatelet therapy. At our
center, the standard antiplatelet
agent for patients with an indi-
cation for OAC who undergo
stent implantation is clopidogrel,
given with a 600-mg loading
dose before the procedure and a
75-mg clopidogrel maintenance
dose (17). There were several
reasons, however, why patients
on triple therapy were either
switched from clopidogrel to
prasugrel or primarily received
prasugrel: 1) patients with HPR
deemed at particularly increased
risk of stent thrombosis (e.g.,
comorbidities, complexity of the
intervention); 2) when patients
with acute coronary syndrome
had already received a 60-mg prasu-
grel loading dose, patients were continued on prasugrel main-
tenance therapy and clopidogrel was not given; 3) patients with
clopidogrel allergy; and 4) patients with previous stent throm-
bosis while receiving treatment with clopidogrel.
Patients in the prasugrel group received a 10-mg main-
tenance dose per day (or 5 mg in patients 75 years and older
or 60 kg body weight). Patients with previous stroke or
transient ischemic attack did not receive prasugrel.
During the procedure, patients were given intravenous
aspirin and heparin or bivalirudin.
Patients were further prescribed aspirin, OAC with a
recommendation for lower INR levels (2.5 to 3.0 in patients
with mechanical valves and 2.0 to 2.5 in other indications)
and other cardiac medications at the discretion of the
patient’s physician.
Assessment of platelet function and tailoring antiplatelet
therapy. ADP-induced platelet aggregation was assessed with
multiple electrode aggregation using an impedance aggregom-
eter (Multiplate Analyzer, Dynabyte, Munich, Germany).
Details of this method were reported previously (18). HPR to
clopidogrel treatment was defined by setting a cutoff point at
468 arbitrary aggregation units (AU)  min (19).
Whole blood was obtained for initial testing from the
arterial sheath and placed into lepirudin-containing plastic
tubes directly after diagnostic angiography and before ad-
ministration of any intravenous PCI-related antithrombotic
agents. Patients in this study cohort who displayed ADP
values 468 AU  min were tested again after a sufficient
delay after initial loading. Blood for subsequent testing was
obtained from an antecubital vein. Those whose levels
remained 468 AU  min received another 600-mg
lopidogrel loading dose and were tested again. If, after the
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
AU  arbitrary units
CI  confidence interval
DES  drug-eluting stent(s)
HPR  high platelet
reactivity
HR  hazard ratio
INR  international
normalized ratio
MACCE  major adverse
cardiac and
cerebrovascular ischemic
event(s)
OAC  oral anticoagulation
PCI  percutaneous
coronary intervention
TIMI  Thrombolysis In
Myocardial Infarctiondditional loading dose, levels still remained 468 AU  tin, the patients received a 60-mg prasugrel loading dose.
nother platelet function test was performed 2 h later to
uantify the antiplatelet action of prasugrel.
tudy endpoints and definitions. The primary clinical
ndpoint of this study was the composite of Thrombolysis
n Myocardial Infarction (TIMI) major and minor bleeding
20) during a 6-month follow-up period. The secondary
tudy endpoint was a composite of major adverse cardiac
nd cerebrovascular ischemic events (MACCE) consisting
f death, myocardial infarction, ischemic stroke, or definite
tent thrombosis. The criteria for the diagnosis of major
leeding included intracranial (confirmed by computed
omography or magnetic resonance imaging of the head) or
linically significant overt signs of hemorrhage associated
ith 50 g/l decrease in hemoglobin level. Minor bleeding
as considered to be observed blood loss and a decrease in
emoglobin level of 30 to 50 g/l or a decrease in hemoglobin
evel 40 g/l if no bleeding site was identifiable (20).
efinite stent thrombosis was defined according to the
cademic Research Consortium criteria (21). All events
ere adjudicated by an event adjudication committee
linded to the antithrombotic regimen of patients and not
nvolved in the follow-up process.
ollow-up. Detailed information regarding the occurrence
f adverse events was obtained in this population during
outine follow-up at 30 days and 6 months for all patients.
Relevant data were collected from source documents and
rospectively entered into a computerized database by spe-
ialized personnel of the data coordinating Intracoronary
tenting and Antithrombotic Research (ISAR) center.
tatistical methods. A comparison of discrete variables,
xpressed as count (percentage), was performed using the
isher exact or the chi-square test, as appropriate. Contin-
ous variables were expressed as mean  SD and compared
ith the unpaired, 2-tailed Student t test if normally
istributed; otherwise, they were expressed as median [25th
o 75th percentile] and statistically analyzed by means of the
ilcoxon rank sum test. Both unadjusted and adjusted risk
stimates were calculated by Cox analysis. In multivariate
nalysis, the independent variables were prasugrel therapy as
ell as clinical presentation, atrial fibrillation, left ventricu-
ar thrombus, and pulmonary embolism/deep vein throm-
osis. Those variables were chosen because they differed
etween the clopidogrel and prasugrel groups with a p value
0.1 at baseline. The Kaplan-Meier method was used for
uilding the event curves.
A 2-sided p value 0.05 was considered to indicate
tatistical significance. All statistical analyses were per-
ormed with the software R (version 2.15.0, The R Foun-
ation for Statistical Computing).
esults
atient population. In total, we included 377 patients who
nderwent DES implantation and were discharged with a
riple therapy recommendation for 6 months or longer
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these patients, 21 (5.6%) received prasugrel and 356 (94.4%)
received clopidogrel. Indication for prasugrel was HPR in
18 patients (85.7%), previous stent thrombosis in 1 patient
(4.8%), ST-segment elevation myocardial infarction in 1
patient (4.8%), and clopidogrel allergy in 1 patient (4.8%).
In the prasugrel group, 16 patients were initially loaded with
clopidogrel and then switched to prasugrel.
Patient baseline characteristics differed between groups.
In the prasugrel group, more patients presented with unsta-
ble disease compared with the clopidogrel group. The
indication for OAC was significantly more often the pres-
ence of a left ventricular thrombus and less often atrial
fibrillation (Table 1). INR values during follow-up were not
significantly different between both groups (prasugrel: 2.1
0.7 vs. clopidogrel: 2.2  0.7; p  0.64).
Clinical outcome. TIMI major and minor bleeding oc-
curred significantly more often in the prasugrel group than
in the clopidogrel group (6 [28.6%) vs. 24 [6.7%); hazard
ratio [HR]: 4.6, 95% confidence interval [CI]: 1.9 to 11.4;
p  0.001 (Fig. 1). There was no significant difference
regarding MACCE (2 [9.5%] vs. 25 [7%]; HR: 1.4, 95%
CI: 0.3 to 6.1]; p  0.61) (Fig. 2, Table 2).
The results of the multivariable Cox proportional hazards
model demonstrated that prasugrel therapy was indepen-
dently associated with 6-month TIMI major and minor
bleeding (adjusted HR: 3.2, 95% CI: 1.1 to 9.1; p  0.03).
In adjusted analysis, there was no difference regarding
Baseline Characteristics of the Study PopulationTable 1 Baseline Characteristics of the Study Population
Characteristics
Prasugrel
(n  21)
Clopidogrel
(n  356) p Value
Age, yrs 71 11 72.6 9 0.48
Women 5 (23.8) 70 (19.7) 0.58
Body mass index, kg/m2 28.6 4 27.7 5 0.35
Glomerular filtration rate,
ml/min/1.73 m2
76.8 32 72.3 33 0.54
Arterial hypertension 12 (57.1) 209 (58.7) 0.89
Diabetes 7 (33.3) 104 (29.2) 0.68
Current smoker 1 (4.8) 33 (9.3) 0.71
Hypercholesterolemia 16 (76.2) 248 (69.6) 0.53
Clinical presentation 0.001
Stable angina 7 (33.3) 231 (64.9)
NSTEMI/unstable angina 6 (28.6) 102 (28.6)
STEMI 8 (38.1) 23 (6.5)
Previous myocardial infarction 4 (19.0) 109 (30.6) 0.33
Previous bypass surgery 2 (9.5) 72 (20.2) 0.39
Ejection fraction 41 13 46 15 0.10
Indication for OAC
Atrial fibrillation 6 (28.6) 286 (80.3) 0.001
Left ventricular thrombus 7 (33.3) 22 (6.2) 0.001
Mechanical valve 2 (9.5) 17 (4.8) 0.29
Pulmonary embolism/DVT 4 (19.0) 26 (7.3) 0.07
Other 2 (9.5) 5 (1.4) 0.10
Values are mean  SD or n (%).
DVT deep vein thrombosis; NSTEMI non–ST-segment elevationmyocardial infarction; OAC
oral anticoagulation; STEMI  ST-segment elevation myocardial infarction.MACCE at 6 months (adjusted HR: 1.1, 95% CI: 0.2 to
5.1; p  0.91).
Platelet function testing. Peri-interventional on clopi-
dogrel treatment ADP-induced platelet aggregation values
(median [IQR]) assessed with multiple electrode aggrega-
tion was 812 [778 to 923] AUmin in the 16 patients who
were switched over to prasugrel. After a 60-mg prasugrel
loading dose, ADP-induced platelet aggregation was 148
(109 to 198) AU  min (p  0.001) (Fig. 3). In the
clopidogrel patients without a switch of treatment, the
ADP-induced platelet aggregation was 229 (152 to 327)
AU  min.
Discussion
In this study, we investigated bleeding and ischemic out-
comes in patients on triple therapy with prasugrel compared
with clopidogrel. Our study suggests that prasugrel therapy
is associated with an increased rate of TIMI major and
minor bleeding compared with clopidogrel in patients who
require OAC after DES implantation. There was no sig-
nificant difference regarding the composite ischemic end-
point between both groups.
Because it is known that the second-generation thien-
opyridine prasugrel compared with clopidogrel is associated
with higher bleeding rates (15), it is a general feeling by
treating physicians that its routine use in patients with triple
therapy is not recommended. There were some clinical
situations, however, in which clopidogrel was assumed not
to be the best option, and we identified 21 patients (18
Figure 1 Composite of TIMI Major and Minor Bleeding
Kaplan-Meier analysis for the primary endpoint (cumulative incidence of Throm-
bolysis In Myocardial Infarction [TIMI] major bleeding and TIMI minor bleeding)
at 6 months.patients with HPR) at our center who received prasugrel
c
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for a low response to clopidogrel are many and include
several genetic as well as nongenetic factors such as patients’
comorbidities and comedications (14). One known agent is
the vitamin K antagonist phenprocoumon, which shares the
same hepatic metabolization pathway as clopidogrel and
when both agents are taken concomitantly, this was shown
to lead to higher ADP-induced platelet aggregation values
(22). There are numerous observational studies that have
clearly linked HPR to a significant increase in ischemic
clinical events (14), whereas at the same time, an increased
Figure 2 Composite of Death, Myocardial Infarction,
Ischemic Stroke, or Stent Thrombosis
Kaplan-Meier analysis for the secondary endpoint (MACCE: cumulative inci-
dence of death, myocardial infarction, ischemic stroke, or stent thrombosis) at
6 months. MACCE  major adverse cardiovascular and cerebrovascular isch-
emic event(s).
Adverse Events at 6 MonthsTable 2 Adverse Events at 6 Months
Adverse Event
Prasugrel
(n  21)
Clopidogrel
(n  356)
Unadjusted HR
(95% CI) p Value
TIMI bleeding
Major and minor 6 (28.6) 24 (6.7) 4.6 (1.9–11.4) 0.001
Major 3 (14.3) 10 (2.8) 6.1 (1.6–22.1) 0.006
Minor 3 (14.3) 14 (3.9) 3.8 (1.1–13.1) 0.04
MACCE 2 (9.5) 25 (7.0) 1.4 (0.3–6.1) 0.61
Death 2 (9.5) 14 (3.9) 2.6 (0.6–11.5) 0.20
Myocardial infarction 0 7 (2.0) — 0.99
Stent thrombosis 0 2 (0.6) — 0.99
Stroke 1 (4.8) 6 (1.7) 3.1 (0.4–25.4) 0.30
Ischemic 0 5 (1.4) 0.99
Hemorrhagic 1 (4.8) 1 (0.3) 18 (1.1–292) 0.04
Values are n (%).
CI  confidence interval; HR  hazard ratio; MACCE  composite of major cardiac anderebrovascular ischemic events: death, myocardial infarction, stent thrombosis, or ischemic
troke; TIMI  Thrombolysis In Myocardial Infarction.response to clopidogrel measured by a low platelet function
is linked to increased bleeding rates (23,24). One may
therefore hypothesize that patients who do not have an
adequate response to clopidogrel have a lower bleeding
risk compared with normal responders, and therefore a
more potent ADP antagonist such as prasugrel may be
given to overcome the low responsiveness and reduce the
ischemic risk. The question remains, however, whether
this has an impact on bleeding outcomes, especially in
those with concomitant OAC therapy.
Since 2009, we routinely measure the peri-procedural
level of P2Y12 inhibition at our center. We have adopted
the practice of tailoring and individualizing antiplatelet
therapy according to the results obtained from platelet
function testing and the patient risk profile. In the present
study, we showed that prasugrel may overcome HPR on
clopidogrel in patients concomitantly treated with OAC;
however, there was a significant increase in TIMI major and
minor bleeding rates in univariable and multivariable anal-
ysis. This may be attributed to the fact that in our popula-
tion, after prasugrel loading, the mean aggregation values
were 148 AU  min, a value that is below the postulated
therapeutic window of optimal platelet response (189 to 467
AU  min) and is associated with increased bleeding rates
(25). Furthermore, we showed that although baseline char-
acteristics such as clinical presentation and indication for
OAC differed, patients receiving prasugrel therapy showed
no difference regarding ischemic events compared with
those receiving clopidogrel. Results of this study have to be
read with caution, however, because the number of patients
and therefore also the number of events were low. An
accurate assessment of the anti-ischemic properties of pra-
Figure 3 Peri-Interventional Platelet Aggregation Values
and After Prasugrel Reloading
Dot density plot analyses of multiple electrode platelet aggregometry (MEA)
measurements for adenosine diphosphate–induced platelet aggregation in the
prasugrel group. Periprocedural values after initial clopidogrel loading (red) and
values after final prasugrel loading (blue) in the patients (n  16) who were
switched from clopidogrel to prasugrel. Dots indicate individual values; line
indicates the median. AU  arbitrary aggregation units.sugrel as part of triple therapy in patients with a low
2065JACC Vol. 61, No. 20, 2013 Sarafoff et al.
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patients. One may argue, however, that the additional
OAC therapy in a triple-therapy patient population may
counterbalance the reduced anti-ischemic properties of a
clopidogrel low response.
Currently, there is much discussion in the medical com-
munity about whether adjusting therapy based on platelet
function testing produces a tangible clinical benefit. So far,
several studies in patients on dual antiplatelet therapy have
recently addressed this issue by intensification of clopidogrel
therapy and have found conflicting results. On the one
hand, intensification of clopidogrel therapy in patients with
acute coronary syndrome undergoing PCI has been shown
to reduce the incidence of ischemic complications (26). On
the other hand, several recent trials failed to show a clinical
benefit of an intensified clopidogrel treatment in stable
patients with HPR after PCI (27–29). In our opinion, based
on the overwhelming evidence of observational studies, in
general, HPR should be regarded as a modifiable risk factor
for ischemic events and current PCI guidelines suggest that
prasugrel might be considered an alternate agent in patients
with a low response to clopidogrel (12). Our study suggests,
however, that in patients receiving triple therapy, switching
to prasugrel is associated with an increased bleeding risk and
therefore assessment of patients’ bleeding and thrombotic
risk is of the utmost importance. Factors that have been
shown to minimize bleeding complications in such a patient
population include lowering the target INR value to 2.0 to
2.5 (30,31) and to coprescribe a proton pump inhibitor (32).
When prasugrel as part of triple therapy is given, it may be
advisable to omit concomitant aspirin therapy because it was
recently shown that therapy with OAC and clopidogrel
alone significantly reduces bleeding events without an in-
crease in ischemic events compared with those receiving
triple therapy including aspirin (33). Another important
issue is the length of triple therapy, which is currently under
investigation in the ISAR-TRIPLE (Testing of a Six-week
Versus a Six-month Clopidogrel Treatment Regimen in
Patients With Concomitant Aspirin and Oral Anticoagulant
Therapy Following Drug-eluting Stenting; NCT00776633)
trial. Current guidelines recommend at least 3 months of triple
therapy after DES implantation and 1 month after bare-metal
stent implantation (10,34).
Study limitations. First, prasugrel and clopidogrel therapy
was not assigned in a randomized manner. Therefore, our
observational study could not prevent significant imbalances
in baseline characteristics, with prasugrel patients presenting
a higher-risk profile than their clopidogrel counterparts.
Second, because of the specific setting of the study, the
number of patients who received prasugrel was very low.
The small size of the prasugrel group limits the ability to
adjust for potential confounding factors and attenuates the
strength of the results. Furthermore, the prasugrel group
consists of a mixed population of patients, most of whom
have shown HPR after clopidogrel loading. For this reason,
our findings cannot be extrapolated to patients in whomprasugrel is given as first-line ADP receptor antagonist
therapy.
Conclusions
We showed that prasugrel is able to overcome HPR to
clopidogrel in patients treated concomitantly with OAC
after DES implantation. However, our study suggests that
substitution of prasugrel for clopidogrel in patients needing
triple therapy increases the risk of bleeding. Specific ran-
domized trials are needed to define the role of newer ADP
receptor antagonists in this setting.
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